North America:
Carbamazepine prices in the North American region embarked optimistically but concluded pessimistically in the second quarter of 2023. These prices followed a trend similar to that of the Indian market throughout the quarter. Initially, prices gradually increased from the previous month at the quarter’s start, holding up until mid-Q2, around May 2023. The rise in Carbamazepine prices stemmed from heightened demand in the pharmaceutical and healthcare industries, benefiting retailers by allowing them to charge higher prices. The Consumer Price Index (CPI) in the US also experienced growth, rising by 0.6% in May 2023 after a 0.3% increase in April. This contributed to the optimistic market trend for Carbamazepine in the US. Additionally, the energy index showed a 3.9% increase. However, prices for Carbamazepine sharply declined as June approached, despite the strengthening CPI, which rose by 0.1% from May to June 2023. Local demand witnessed a noticeable decline, and analysts and business leaders suggested that the US inflation rate was on the decline. Nevertheless, significant underlying inflation was still present, surpassing the Federal Reserve’s target, despite decreasing energy prices. Local Carbamazepine suppliers had ample stock, enabling them to meet regional demand.
Asia Pacific:
Throughout Q2 2023, Carbamazepine prices, a crucial Active Pharmaceutical Ingredient in the APAC region, displayed a descending pricing sentiment. Prices dropped notably throughout April and maintained this trend, reflecting positive demand expectations until mid-Q2, only to experience a significant decline as the quarter ended in June. Domestic Carbamazepine consumption increased in April 2023, with moderate inquiries from both domestic and overseas markets. Manufacturing PMI fell in April from 51.9 to 49.2, dipping below the 50-point threshold that signifies monthly growth versus contraction. The supply was sufficient to meet the month’s total demand. However, manufacturers began replenishing shelves in May as supply diminished, bolstering production. The May price trend found support from suppliers and merchants selling goods at elevated prices. India’s Purchasing Managers’ Index (PMI) increased to 58.7 in May 2023 from 57.2 in April 2023, driven by robust growth in manufacturing and services activities. The RBI raised interest rates twice in 2023 to curb inflation. June’s PMI for India stood at 53.9, slightly below May’s 54.0, indicating declining purchasing activity and reduced export momentum. The Carbamazepine prices aggregated at USD 68694.95/MT IP Ex-Vadodara.
Carbamazepine Prices: https://www.chemanalyst.com/Pricing-data/carbamazepine-1525
Europe:
Carbamazepine prices in the German market mirrored a similar trajectory to the APAC region during Q2 2023. The quarter’s onset saw price surges, maintaining higher levels until mid-Q2, aided by the easy availability of downstream Carbamazepine from exporting nations like India at lower prices than usual. However, prices gradually decreased as June approached, maintaining a stable demand-supply balance within the region. Falling raw material prices for API production contributed to the price decline. Geopolitical tensions between Russia and Ukraine disrupted supply chains, exacerbated by elevated energy prices, impacting both consumers and businesses and reducing economic activity. Rising energy costs posed a significant challenge for the German economy, which heavily relies on energy imports, affecting consumers and businesses alike.
Contact Us:
ChemAnalyst
420 Lexington Avenue, Suite 300,
New York, NY, United States, 10170
Call +1 3322586602
Email: sales@chemanalyst.com
Website: https://www.chemanalyst.com